Imiquimod 5-percent cream does not alter the natural history of recurrent herpes genitalis: A phase II, randomized, double-blind, placebo-controlled study

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 10, 2002, Pages 3243-3248

  Schacker, Timothy W ^a   Conant, Marcus ^a   Thoming, Christopher ^a   Stanczak, Tamara ^a   Wang, Zengri ^a   Smith, Michael ^a   Beutner, Karl ^a   Fife, Kenneth ^a   Guy, Harold ^a   Livengood, Charles ^a   Parrish, S ^a   Markert, M ^a   Hannon, S ^a   Christiansen, C ^a   Klebe, M ^a   Farladeaux, B ^a   Edgren, A ^a   Meng, T C ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; IMIQUIMOD; INTERLEUKIN 12; PLACEBO;

ADULT; ARTICLE; BURN; CLINICAL ARTICLE; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; EDEMA; ERYTHEMA; FEMALE; GENITAL HERPES; HUMAN; IMMUNE SYSTEM; MALE; PAIN; PAPILLOMA VIRUS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENT DISEASE; SKIN TINGLING; TREATMENT OUTCOME; ULCER;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, TOPICAL; ADOLESCENT; ADULT; AGED; AMINOQUINOLINES; DOUBLE-BLIND METHOD; FEMALE; HERPES GENITALIS; HUMANS; MALE; MIDDLE AGED; RECURRENCE; TREATMENT OUTCOME;

EID: 0036784341     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.10.3243-3248.2002     Document Type: Article

References (27)

1. New antiherpesvirus agents: Their targets and therapeutic potential
2. Comparison of Western blot (immunoblot) and glycoprotein G-specific immunodot enzyme assay for detecting antibodies to herpes simplex virus types 1 and 2 in human sera
3. Recurrence rates in genital herpes after symptomatic first-episode infection
4. Effects of therapy with an immunomodulator (imiquimod-R-837) alone and with acyclovir on genital HSV-2 infection in guinea-pigs when begun after lesion development
5. Recombinant glycoprotein vaccine for the prevention of genital HSV-2 infection: Two randomized controlled trials
6. A double-blind study of oral acyclovir for suppression of recurrences of genital herpes simplex virus infection
7. Self-administered topical 5% imiquimod cream for external anogenital warts
8. Herpes simplex virus type 2 in the United States, 1976-1994
9. Characterization of the altered cutaneous reactivity of transgenic mice whose keratinocytes overexpress B7-1
10. Posttherapy suppression of genital herpes simplex virus (HSV) recurrences and enhancement of HSV-specific T-cell memory by imiquimod in guinea pigs
11. The frequency of unrecognized type 2 herpes simplex virus infection among women: Implications for the control of genital herpes
12. Underdiagnosis of genital herpes by current clinical and viral-isolation procedures
13. Resistance to herpes simplex virus-type 1 (HSV-1)
14. Long-term acyclovir suppression of frequently recurring genital herpes simplex virus infection
15. Oral famciclovir for suppression of recurrent genital herpes simplex virus infection in women. A multicenter, double-blind, placebo-controlled trial
16. Seroprevalence of herpes simplex virus infections in a family clinic
17. Valaciclovir for the suppression of recurrent genital HSV infection: A placebo controlled study of once daily therapy
18. Famciclovir. A review of its pharmacological properties and therapeutic efficacy in herpesvirus infections
19. Valaciclovir for the suppression of recurrent genital herpes simplex virus infection: A large-scale dose range-finding study
20. TM)
21. Application of a topical immune response modifier, resiquimod gel, to modify the recurrence rate of recurrent genital herpes: A pilot study
22. Prospects for control of herpes simplex virus disease through immunization
23. Suppression of frequently recurring genital herpes. A placebo-controlled double-blind trial of oral acyclovir
24. Immunotherapy of recurrent genital herpes with recombinant herpes simplex virus type 2 glycoproteins D and B: Results of a placebo-controlled vaccine trial
25. Medical care expenditures for genital herpes in the United States
26. Modulation of TH1 and TH2 cytokine production with the immune response modifiers R-848 and imiquimod
27. Reactivation of genital herpes simplex virus 2 infection in asymptomatic seropositive persons